COGT Stock — Cogent Biosciences, Inc.

Cogent Biosciences, Inc. (COGT)

Updated October 16, 2026.

COGT is a Stock. Total return is -33.6% over the past 8.6 years, 263.5 points behind SPY at 229.9%.

Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases, with its lead candidate bezuclastinib in Phase 3 trials for systemic mastocytosis and gastrointestinal stromal tumors, alongside earlier-stage programs targeting mutations in fibroblast growth factor receptor, ErbB2, and PI3K. The company does not currently distribute to shareholders. Cogent Biosciences appeals to investors seeking exposure to clinical-stage biotech development with potential for long-term capital appreciation rather than current income.

COGT performance versus SPY

Price and return data through 2026-10-16.

Total return is -33.6% over the past 8.6 years, 263.5 points behind SPY at 229.9%. Over the past year its total return — price change plus distributions reinvested — is 80.4%. Its deepest 1-year drawdown was 34.4%.

COGT key facts

Asset type

Stock

Asset class

Equity

Inception date

03/29/2018

Distribution frequency

None

Last close

$29.52 (as of 2026-10-16)

Market cap

$5,122,457,469

Average volume

2783005.0

Payment date

11/09/2020

Beta

0.314

Payout ratio

0.0%

EPS

$-2.16

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

COGT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 34.4%.

Who may consider COGT — and who may not

It is a weaker fit for investors who need monthly cash flow (COGT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on COGT

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions